Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone vs pasireotide to prevent pancreatic fistula after pancreatic resection
2016-000212-16Phase 2Completed
- Sponsor
- Helsinki University Hospital
- Start
- Mar 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in Postoperative pancreatic fistula (POPF) and pancreatic fistula (POPF) comparing Hydrocortisone arm with Pasireotide arm (2 arms). Primary endpoint: Comprehensive complication index. Started Mar 2016; status: completed.
02
Drugs
hydrocortisonepasireotide LAR
03
Conditions
Postoperative pancreatic fistula (POPF)pancreatic fistula (POPF)
Beyond the preview
Go deeper on 2016-000212-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000212-16.